MAT2A inhibition in MTAP-/- tumors confers mechanistic vulnerabilities to multiple clinically actionable synthetic lethal drug combinations

被引：1
|
作者：
Gerrick, Kimberline Y.
Laraio, Jenny
Annen, Kelsey
Tran, Hoang
Fischer, Marcus M.
Freyman, Yevgeniy
Sharma, Geeta
Bishof, Isaac
Federowicz, Stephen
Pankajakshan, Divya
Neilan, Claire L.
Mangatt, Biju
Mazurek, Anthony
Lackner, Mark R.
White, Michael
Mounir, Zineb
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-1637
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1637
引用
收藏
页数：3
相关论文
共 3 条
  • [1] The mechanistic basis of both deep and durable antitumor activity by combinatorial inhibition of MAT2A and PRMT5 in MTAP-deleted tumors
    Garbett, D.
    Rao, A. A.
    Fischer, M. M.
    Belmontes, B.
    Slemmons, K.
    Appel, M. J.
    Fang, Z.
    Choy, R.
    Tyler, S. R.
    Vivian, J.
    Freyman, Y.
    Magallanes, K.
    Lanham, P.
    Rathore, A.
    Li, A.
    Aubi, O.
    Hughes, P. E.
    Teriete, P.
    White, M. A.
    Neilan, C. L.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S84 - S84
  • [2] Combined inhibition of MTAP and MAT2a mimics synthetic lethality in tumor models via PRMT5 inhibition
    Bedard, Gabriel T.
    Gilaj, Nord
    Peregrina, Karina
    Brew, Isabella
    Tosti, Elena
    Shaffer, Karl
    Tyler, Peter C.
    Edelmann, Winfried
    Augenlicht, Leonard H.
    Schramm, Vern L.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2024, 300 (01)
  • [3] A phase I study of synthetic lethal, IDE397 (MAT2A inhibitor) as a monotherapy and in combination with chemotherapy in advanced solid tumors harboring MTAP deletion
    Johnson, M. L.
    Rodon, J.
    Aljumaily, R.
    Villalona-Calero, M.
    Borazanci, E.
    Pishvaian, M.
    Turk, A.
    Carvajal, R. D.
    Mantia, C.
    Giaccone, G.
    Mounir, Z.
    Patel, A.
    Maurer, M.
    Neilan, C.
    Rajendran, D.
    Ganesan, U.
    Hinkle, J.
    Tolcher, A. W.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S766 - S767
1